(since 1990)

Zimmerman MS, Cole RA, Woods KL, Rabassa AA and Ertan A: The role of enteroscopy in small bowel disease. Gastroint Endosc 41(4):313, 1995.

Rabassa AA, Cole RA, Ertan A, Anand B, Zimmerman M, Woods KL: Endoscopic management of bile duct injury following cholecystectomy. Gastroint Endosc 41(4):464, 1995.

Ertan A, Syed K: Endoscopic pancreatic stenting (EPS) after endoscopic pancreatic papilla dilation (EPPD) without pancreatic sphincterotomy. Amer J Gastroenterol 90(9):196, 1995.

Ertan A, Syed K, Woods K, Cole R: Novel tube decompression of colonic acute pseudoobstruction. Amer J Gastroenterol 90(9)343, 1995.

Younes M, Ertan A, Lechago LV, Somoano J, Lechago J: The human erythrocyte glucose transporter glut1 is expressed as a late event during neoplastic progression in Barrett's metaplasia. The United States and Canadian Academic of Pathology Annual Meeting, Washington DC, March 1996.

Younes M, Ertan A, Lechago L, Lechago J: Sensitivity and specificity of p53. protein acumulation as a marker of malignant potential in Barrett's metaplasia. Am J Gastroenterol 91: 1901, 1996.

Ertan A: The efficacy and safety of endoscopic transpapillary drainage of pancreatic pseudocysts (ETDPP) without pancreatic sphincterotomy. Am J Gastroenterol 91: 1932, 1996.

Younes M, Ertan A, Lechago LV, Somoano J, Lechago J: p53 protein accumulation is an early indicator of malignant potential in Barrett's metaplasia. Accepted for publication in the United States and Canadian Academic of Pathology Annual Meeting, Washington DC, March 1996.

Castell D, Sigmund C, Patterson D, Ertan A, et al: Cisapride 20 mg bid provides effective daytime and nighttime relief in patients with symptoms of chronic gastroesophageal reflux disease. Gastroenterology 112:84, 1997.

Woods, KL, Anand BS, Cole R, Killip DM, Ertan A, et al: Comparative assessment of biopsy forceps for upper endoscopy: Pathologist blinded randomized study. Gastrintest Endosc. 102:45, 1997.

Younes M, Santella RM, Ayub K, Younes P, Pathak MHS.M, Ertan A: Detection of oxidative DNA damage (ODD) in patients with reflux esophagitis (RE) by immunohistochemistry. Am J Gastroenterol 92:1606, 1997.

Younes M, Lechago J, Ertan A, et al: Comparison between brush cytology (Cy) and Biopsy (Bx) in the detection of dysplasia, p53 accumulation, and Glut1 expression in patients with Barrett's Metaplasia (BM). Am J Gastroenterol 92:1606, 1997.

Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Canales L, Meriano F, Solcher D, Barroso A, Balsaver A, Ertan A: Relationship between dysplasia, p53 protein, DNA ploidy, glut1, and Rb protein in Barrett's Metaplasia (BM). Am J Gastroenterol 92:1607, 1997.

Younes M, Lechago J, Chakraborty S, Bridges M, Canales L, Meriano F, Solcher D, Barroso A, Balsaver A, Carlson N, Ertan A: Dysplasia, p53 Protein, DNA Ploidy, and GLUT1, in Barrett's Metaplasia (BM): preliminary results of prospective study. Am J Gastroenterol 93:1628, 1998.

Younes M, Ertan A, Lechago J,Finnie D. Expression of Fas (CD95/APO1) in Barrett's metaplasia (BM), dysplasia and carcinoma. Am J Gastroenterol 93:1628, 1998.

Mody DR, Ertan A, Lechago J, Bridges M, Canales L, Meriano F, Solcher D, Barroso A, Carlson N. The thinprep method is superior to cytospins in preparing cytologic preparations from patients with Barrett's metaplasia. Am J Gastroenterol 93:1629, 1998.

Younes M, Santella R, Younes P, Pathak M, Ertan A. Persistent oxidative DNA damage in Barrett's epithelium in patients treated with H2 blockers or proton pump inhibitors. Gastroenterology 116:1600; 1999.

Younes M, Schwartz MR, Ertan A, Finnie D, Younes A. FAS ligand (FASL) expression in esophageal carcinomas and their nodal metastases. Gastroenterology 116:2348; 1999.

Ertan A. Long-term results after endoscopic pancreatic stenting (EPS) without pancreatic papillotomy (PP) in acute recurrent pancreatitis (ARP) due to pancreas divisum (PD). Gastroint Endosc, 519:187, 1999.

Ertan A. Infliximab (Anti-TNF-alfa antibody) in treatment of rectovaginal fistula with Crohn's disease. Am J Gastroenterology, 94:1605, 1999.

Younes M, Ertan A, et al. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia. Scandinavian University Press, 2000.

Liu L, Ergun G, Ertan A, et al. Oxidative DNA damage (ODD) detected in esophageal biopsies of patients with reflux symptoms and normal PH studies. Gastroenterology. 2003.

Liu L, et al & Ertan A. Mutations in exon 2 of the p53 gene in Barrett's metaplasia Gastroenterology. 2003.

Shannon G, Ertan A, Qureshi: Hyperbaric oxygen therapy for pneumatosis coli. Am J Gastroenterol., 987: A365, 2002

Chen X, Lechago J, Ertan A, et al. Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia. Gastroenterology, 124: 1285, 2003.

Liu L, et al & Ertan A. Frequent polymorphism in exon 4 of the p53 gene in Barrett's metaplasia. Gastroenterology, 2003.

Lui L, Ergun G, Ertan A, et al: Detection of oxidative DNA damage in esophageal biopsies of patients with reflux symptoms and normal pH monitoring. Gastroenterology, 124: 2091, 2003.

Younes M, Ertan A, et al:  Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia.  Am J Gastroenterol, 100: 7, 2005.

Younes M, Liu B, Wang J, Lechago J, Ertan A, et al. P53 mutation does not predict malignant progression in biopsies of patients with Barrett’s metaplasia. Gastroenterology, 130: 565, 2006.

Brown K, Younes M, Ertan A, et al. The utility of cytologic diagnosis in patients with Barrett’s metaplasia. Gastroenterology, 134: 433, 2008.

Younes M, Lauwers YG, Ertan A, et al. The significance of an indefinite for dysplasia diagnosis in patients with Barrett’s metaplasia. Gastroenterology, 134, 435, 2008.

Brown K, Younes M, Ertan A, et al. P53 immunostaining predicts malignant progression in Barrett’s metaplasia. Gastroenterology, 134, 432, 2008.

Ergun A, Barroso, Schwartz M, Ertan A. Radiofrequency ablation of Barrett’s esophagus may exacerbate eosinophilic esophagitis. Am J Gastroenterol 103, 41, 2008.

Blackmon S, Zaheer I, Barroso A, Ertan A. Photodynamic therapy versus radiofrequency ablation therapy in Barrett’s dysplasia. Am J Gastroenterol 104, 1598, 2009.

Villa N, El-Seraq H, Younes M, Ertan A.  Eosinophillic esophagitis after radiofrequency ablation for Barrett's esophagus:  Causal or coincidence?   Am J Gastroenterol 106, S3, 2011.

Reddy S, Khanijow V, Varla A, Ertan A.  Hereditary angloedema as a cause of abdominal pain.   Am J Gastroenterol 106, S336, 2011.

Shaheen NJ, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, et al: Prior fundoplication does not improve subsequent safety or efficacy outcomes of radiofrequency ablation (RFA): Results from the US RFA Registry. Gastroenterology 2012.

Shaheen NJ, Bulsiewicz WJ, Rothstein RI, Komanduri S, Wolfsen C, et al, Ertan A: Eradication rates of Barrett’s esophagus using radiofrequency abalation (RFA): Results from the US RFA Registry. Gastroenterology 2012.

Bulsiewicz WJ, Infantolino A, Ertan A, et al: Length of Barrett’s esophagus predicts likelihood of complete eradication of intestinal metaplasia and number of treatment sessions of radiofrequency ablation: Results from the US RFA Registry. Gastroenterology 2012.

Shaheen NJ, Bulsiewicz WJ, RothsteinRI, Triadafilopoulos G, Wolfsen HC, Komanduri S, Lyday WD, Ertan A, et al: Radiofrequeny ablation (RFA) safely treats Barrett’s esophagus in a nationwide, multicenter cohort: Results from the US RFA Registry. Gastroenterology 2012.

Bulsiewicz WJ, Infantolino A, LightdaleCJ, Ertan A, et al:  The safety and efficacy of endoscopic mucosal resection prior to radiofrequency ablation for dysplastic Barrett’s esophagus: Results from the US RFA Registry. Gastroenterology 2012.

Please download Dr. Ertan's CV for up-to-date abstract list.